General Information


We are a biopharmaceutical company utilizing our differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, our approach relies on the human immune system to direct us to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.

Employees: 85
Founded: 2011
Contact Information
Address 500 Saginaw Drive, Redwood City, CA 94063, US
Phone Number (650) 595-2595
Web Address
View Prospectus: Atreca
Financial Information
Market Cap $455.3mil
Revenues $0 mil (last 12 months)
Net Income $-43.9 mil (last 12 months)
IPO Profile
Symbol BCEL
Exchange NASDAQ
Shares (millions): 7.4
Price range $17.00 - $17.00
Est. $ Volume $125.0 mil
Manager / Joint Managers Cowen and Company/ Evercore/ Stifel
CO-Managers Canaccord Genuity/ Brookline Capital Markets
Expected To Trade: 6/20/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change